Polydeoxyribonucleotide (PDRN) microbial limit testing is a critical quality control procedure that verifies the microbiological safety of PDRN active substances, formulations, medical devices, and cosmetic ingredients by quantifying bioburden and screening for objectionable microorganisms. This testing is typically performed in accredited third-party laboratories in accordance with harmonized pharmacopoeial standards such as USP <61>/<62>, Ph. Eur. 2.6.12/2.6.13, and the Chinese Pharmacopoeia, as well as ISO methods for cosmetics and medical devices. This article provides a comprehensive technical overview of PDRN microbial limit testing, including sample types, test items, analytical methods, acceptance criteria, and practical regulatory considerations.
Technical Overview
Polydeoxyribonucleotide (PDRN) is a mixture of linear deoxyribonucleotides of varying chain lengths, typically ranging from approximately 50 to 2,000 base pairs, obtained through controlled depolymerization of DNA extracted from salmon or trout milt. Owing to its regenerative, anti-inflammatory, and tissue-repair properties, PDRN is widely used in injectable aesthetic and therapeutic formulations, wound-care products, and dermocosmetic ingredients. Because these applications involve parenteral, mucosal, or compromised-skin exposure, stringent microbiological control is essential throughout manufacturing.
Microbial limit testing (MLT) is a compendial microbiological examination designed for non-sterile products and raw materials. It quantifies the total aerobic microbial count (TAMC), the total combined yeasts and molds count (TYMC), and confirms the absence of specified objectionable organisms such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella species, and Candida albicans. For PDRN specifically, MLT is applied to incoming raw materials, intermediates, non-sterile finished products, and pre-sterilization bioburden monitoring, while terminally sterilized or aseptically filled PDRN injectables additionally require a separate compendial sterility test.
Testing is typically conducted against harmonized standards, including USP General Chapters <61> and <62>, European Pharmacopoeia sections 2.6.12 and 2.6.13, and Chinese Pharmacopoeia chapters 1105 and 1106, with acceptance criteria guided by USP <1111>, Ph. Eur. 5.1.4, and Chinese Pharmacopoeia chapter 1107. For cosmetic and medical device applications, ISO 21149, ISO 16212, ISO 21150, ISO 22717, ISO 22718, ISO 17516, and ISO 11737-1 provide the applicable methodological framework.
Testing Samples
PDRN Bulk Substances and Active Pharmaceutical Ingredients
Purified PDRN or sodium PDRN supplied as lyophilized powders, hygroscopic solids, or concentrated aqueous solutions is tested at the API qualification stage to verify that upstream extraction, depolymerization, purification, and drying steps have not introduced unacceptable microbial contamination. Sampling is performed under aseptic conditions using representative units from each batch.
PDRN Injectable and Sterile Formulations
Although sterile PDRN injections are ultimately controlled by sterility testing per USP <71> or Ph. Eur. 2.6.1, microbial limit testing and bioburden determination are performed on bulk solution prior to sterilization and on any non-sterile excipients. This supports validated sterilization processes by demonstrating that pre-sterilization bioburden remains within justified limits.
PDRN-Containing Medical Devices
Wound dressings, dermal matrices, microneedling products, and other devices that deliver or are impregnated with PDRN are evaluated for bioburden according to ISO 11737-1 or GB/T 19973.1, ensuring that microbial levels remain compatible with the validated sterilization or aseptic processing method.
Cosmetic and Dermocosmetic Products
PDRN serums, creams, ampoules, and skin-booster products intended for cosmetic use are tested under ISO 21149, ISO 16212, and related ISO 18415-series methods, with limits defined by ISO 17516 or regional cosmetic regulations such as Regulation (EC) No 1223/2009. Products applied to the eye area, mucous membranes, or children under three years are subject to stricter category limits.
Process Water, Intermediates, and Environmental Samples
Purified water, water for injection, buffer solutions, in-process intermediates, and environmental monitoring samples from Grade A/B and controlled production areas are routinely tested to support overall microbiological control strategy for PDRN manufacturing.
Testing Items
A standard PDRN microbial limit testing panel includes the following items:
- Total Aerobic Microbial Count (TAMC) expressed in CFU per gram or per milliliter of sample.
- Total Combined Yeasts and Molds Count (TYMC) expressed in CFU per gram or per milliliter of sample.
- Absence of Escherichia coli, typically in 1 g or 1 mL of product.
- Absence of Staphylococcus aureus for topical, dermal, and mucosal applications.
- Absence of Pseudomonas aeruginosa for topical, dermal, and mucosal applications.
- Absence of Salmonella species for oral and certain biological materials.
- Absence of Candida albicans for vaginal, mucosal, and eye-area cosmetic products.
- Bile-tolerant Gram-negative bacteria count for certain oral and raw material specifications.
- Method suitability (validation) demonstrating adequate microbial recovery in the presence of the PDRN sample matrix.
Typical acceptance criteria for non-sterile pharmaceutical preparations, per USP <1111> and Ph. Eur. 5.1.4, include TAMC not exceeding 100 CFU/mL or g for aqueous oral and topical preparations, up to 1,000 CFU/g for non-aqueous oral preparations, and absence of the specified indicator organisms in 1 g or 1 mL. Under ISO 17516, cosmetic products intended for children under three years, the eye area, or mucous membranes must not exceed 100 CFU/g or mL, while other cosmetics are limited to 1,000 CFU/g or mL. Company-specific internal specifications for PDRN raw materials are frequently set tighter than compendial limits to provide safety margins for downstream sterile processing.
Testing Methods
Method Suitability Validation
Before routine testing, the method must be validated to confirm that the PDRN matrix does not inhibit microbial growth. Samples are spiked with reference strains such as Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 8739, Bacillus subtilis ATCC 6633, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404. Recovery must fall within the compendial acceptance range, generally 50% to 200% of the control count. Where preservatives or antimicrobial excipients are present, neutralizing agents such as lecithin, polysorbate 80, or sodium thiosulfate are incorporated into diluents and media.
Plate Count Methods
For TAMC, the sample is dissolved or suspended in buffered sodium chloride-peptone solution pH 7.0, plated in duplicate using the pour-plate or spread-plate technique with casein soybean digest agar (TSA/CSDA), and incubated at 30–35°C for 3–5 days. For TYMC, Sabouraud dextrose agar with antibacterial antibiotics is used, with incubation at 20–25°C for 5–7 days. Counts are calculated from plates yielding 30–300 CFU (or 25–250 CFU per some pharmacopoeial editions) and reported per gram or milliliter of original sample.
Membrane Filtration
For filterable PDRN solutions with low expected bioburden, the membrane filtration method offers superior sensitivity. The sample or its dilution is passed through a 0.45 µm membrane, which is then rinsed to remove residual matrix and transferred onto the surface of TSA or SDA plates for incubation under the conditions described above. This approach is preferred for aqueous injectable intermediates and purified water systems.
Detection of Specified Microorganisms
Specified organism screening follows a two-stage enrichment and selective isolation scheme. Pre-enrichment in soybean–casein digest broth is followed by selective enrichment, for example Enterobacteriaceae enrichment broth for bile-tolerant Gram-negative bacteria, and plating onto selective or chromogenic media such as MacConkey agar for E. coli, cetrimide agar for P. aeruginosa, mannitol salt or Baird-Parker agar for S. aureus, xylose lysine deoxycholate agar for Salmonella, and chromogenic Candida agar for C. albicans. Presumptive colonies are confirmed by biochemical identification, MALDI-TOF mass spectrometry, or nucleic acid amplification techniques.
Rapid Microbiological Methods
Compendially acceptable rapid alternatives, including ATP bioluminescence, auto-fluorescence-based enumeration, flow cytometry, and quantitative PCR assays, can shorten time-to-result from several days to hours. Implementation requires validation in accordance with USP <1223>, Ph. Eur. general chapter 5.1.6, and PDA Technical Report No. 33, demonstrating equivalence or superiority to the traditional culture-based method.
Complementary Endotoxin Testing
Although distinct from microbial limits, bacterial endotoxin testing by LAL gel-clot, kinetic turbidimetric, or chromogenic methods per USP <85>, Ph. Eur. 2.6.14, or Chinese Pharmacopoeia chapter 1143 is commonly performed alongside MLT for PDRN materials destined for parenteral use, given the inherent endotoxin risk associated with biological raw materials of aquatic origin.
Applications
PDRN microbial limit testing supports quality assurance and regulatory compliance across the entire product lifecycle. Key applications include:
- Batch release testing of non-sterile PDRN raw materials, cosmetic ingredients, and finished products.
- Pre-sterilization bioburden control for sterile PDRN injectable manufacturing.
- Regulatory submissions to agencies such as the FDA, EMA, China NMPA, and Korea MFDS, including IND, NDA, and cosmetic product safety dossiers.
- Cosmetic Product Safety Reports under Regulation (EC) No 1223/2009, supported by ISO 17516 compliance data.
- Medical device bioburden characterization and sterilization validation per ISO 11737-1 and GB/T 19973.1.
- Microbiological stability programs verifying that microbial quality is maintained through the claimed shelf life.
- Supplier qualification, incoming material control, and investigation of microbial excursions or contamination events.
- Research-grade PDRN characterization for preclinical and clinical study material certification.
FAQ
Why is microbial limit testing required for PDRN if injectable products are sterile?
Sterile PDRN injectables must pass a compendial sterility test, but microbial limit testing remains essential for controlling raw materials, excipients, and pre-sterilization bulk solutions. Excessive bioburden can overwhelm sterilization processes, increase endotoxin load, and degrade nucleic acid integrity, so MLT forms part of the overall contamination control strategy.
What are the typical acceptance criteria for PDRN products?
For non-sterile pharmaceutical preparations, TAMC limits of 100 CFU/g or mL for aqueous and topical products and up to 1,000 CFU/g for non-aqueous oral products are common, together with absence of specified organisms in 1 g or 1 mL. Cosmetics generally follow ISO 17516, with 100 CFU/g or mL for products used on children under three, the eye area, or mucous membranes, and 1,000 CFU/g or mL for other products. Manufacturers often adopt tighter internal specifications.
How long does a standard microbial limit test take?
Traditional culture-based TAMC and TYMC enumeration requires 3–7 days of incubation, and specified organism screening with confirmation may extend the total timeline to 7–14 working days. Method suitability validation, performed initially and after formulation or process changes, adds additional time and should be scheduled in advance of routine batch testing.
Does the PDRN matrix interfere with the test?
PDRN itself is water-soluble and exhibits no significant antimicrobial activity, but preservatives, chelating agents, or formulation excipients can inhibit recovery. Method suitability testing with spiked reference strains, including the use of neutralizers where required, demonstrates that recovery is not compromised and must be documented before routine testing is valid.
Can rapid microbiological methods replace compendial testing?
Yes, provided the rapid method is validated per USP <1223> and Ph. Eur. 5.1.6 and, for regulated products, accepted by the relevant competent authority. Rapid methods such as ATP bioluminescence, flow cytometry, and qPCR offer faster results and are increasingly used for in-process bioburden monitoring and raw material screening.
Which standards govern PDRN microbial limit testing internationally?
Pharmaceutical testing follows USP <61>, <62>, and <1111>, Ph. Eur. 2.6.12, 2.6.13, and 5.1.4, and Chinese Pharmacopoeia chapters 1105–1107. Cosmetic testing relies on ISO 21149, ISO 16212, ISO 21150, ISO 22717, ISO 22718, and ISO 17516, while medical device bioburden testing follows ISO 11737-1 or the equivalent GB/T 19973.1 standard.